Purpose: To review the epidemiology, clinical features, and treatment of seizures secondary to pediatric brain tumors. Method: Literature review. Results: Pediatric brain tumors are the most common solid pediatric tumor and the most common cause of death in pediatric cancer. Seizures are one of the most common symptoms of pediatric brain tumors. Factors associated with increased risk of seizures include supratentorial location, gray matter involvement, low-grade, and certain histological features-especially dysembryoplastic neuroepithelial tumor, ganglioglioma, and oligodendroglioma. Leukemic infiltration of the brain, brain metastases of solid tumors, and brain injury secondary to chemotherapy or radiotherapy can also cause seizures. Mechanisms by which brain tumors cause seizures include metabolic, and neurotransmitter changes in peritumoral brain, morphologic changes -including malformation of cortical development -in peritumoral brain, and presence of peritumoral blood products, gliosis, and necrosis. As there is a high degree of uncertainty on how effective different antiepileptic drugs are for seizures caused by brain tumors, choices are often driven by the interaction and side effect profile. Classic antiepileptic drugsphenobarbital, phenytoin, or carbamazepine -should be avoided as they may alter the metabolism of chemotherapeutic agents. Newer drugs -valproate, lamotrigine, topiramate, zonisamide, and levetiracetam -may be the preferred option in patients with tumors because of their very limited interaction with chemotherapy. Conclusion: Seizures are a common presentation of pediatric brain tumors, especially in supratentorial tumors with gray matter involvement. Antiepileptic drug therapy is usually driven by the interaction and side effect profile and newer drugs with few interactions are generally preferred.
Introduction
Pediatric brain tumors are the second cause of pediatric cancer [1] [2] [3] [4] and the leading cause of cancer mortality in children [5, 6] . Seizures are one of the most common symptoms of pediatric brain tumors, both as presenting symptom or appearing during the course of the disease [7, 8] . In this review of the literature, we summarize the main epidemiology, clinical features, and treatment of seizures caused by pediatric brain tumors. We also provide a brief summary on the current understanding of the pathophysiology that may contribute to seizures in patients with brain tumors.
Epidemiology
Approximately 1 in 285 children will be diagnosed with cancer before age 20 years, and approximately 1 in 530 young adults between the ages of 20 and 39 years is a childhood cancer survivor [4] . Brain cancers are the second most common cancer in children (after leukemias) accounting for 20-25% of cases in this age range and the third most common in adolescents accounting for approximately 10% of cases in this age range [2, 4] . Further, brain tumors are the leading cause of pediatric cancer-related mortality [6] and the largest cause of years of potential life lost in children accounting for 31% of potential life years lost among cancer and 1.4% among all causes [5] . Although pediatric brain tumors most
Characteristics of seizures in children with brain tumors
In a meta-analysis of presenting signs and symptoms of pediatric brain tumor, seizures were the fifth more common clinical presentation only behind headache, nausea and vomiting, abnormal gait or coordination, and papilledema [8] . Further, considering only supra-tentorial tumors, seizures were the second more common clinical presentation -behind symptoms of increased intracranial pressure -occurring in 38% of cases [8] .
The probability of a tumor presenting with seizures depends on several factors such as tumor histology and tumor location in the brain. Low-grade tumors are more epileptogenic, probably reflecting longer survival and, therefore, a longer time period to develop epilepsy [12] . In an adult series of 1028 gliomas, seizures occurred in 49% of patients with glioblastoma, in 69% of patients with anaplastic glioma, and in 85% of patients with low-grade glioma [13] . In a pediatric series of 298 children with brain tumors, seizures occurred in 81% of glioneuronal tumors, in 71% of high-grade gliomas, and in 80% of oligodendroglioma while they were rare in medulloblastoma (8%), germ cell tumor (11%), atypical teratoid rhabdoid tumor (0%), and pineocytoma or pineoblastoma (0%) [7] . In the same pediatric series, seizures were more frequent among tumors involving the cerebral cortex (53%) than in those with midline (18%) and infratentorial (9%) location [7] . Although infratentorial tumors are less frequently associated with seizures as compared to supratentorial tumors, seizures tend to occur through mass effect, hydrocephalus, or metastases, and their relative frequency makes them a relevant contributor to seizures in children with brain tumors [7] .
Despite tumors being focal, seizure semiology is often generalized and, when focal, it may or may not reflect the location of the brain tumor. In a series of 100 adult patients with primary cerebral tumors, the most frequent semiology was tonic-clonic (without focal signs in 26% of patients and with focal signs in 22% of patients), focal motor in 26% of patients, focal with dyscognitive symptoms in 10% of patients, somatosensory in 8% of patients, aphasic in 4%, and other in 4% [14] . The most frequent seizure sequence (43%) consisted of a primarily or secondarily generalized seizure as initial presentation followed after a few days or weeks by focal seizures, while the reverse sequence of focal seizures at initial presentation followed by secondarily generalized seizures was less frequent (33%) [14] . In this series, 42% of patients had an isolated seizure or less than 1 seizure per month, and 64% were on monotherapy [14] . In a large pediatric series of 298 children with brain tumors, 71 patients had seizures [7] . Most seizures were generalized/secondarily generalized (35%) or focal with dyscognitive features (34%), followed by unclassified seizure type (21%), and focal (10%) [7] . In this series, 44% of patients were on monotherapy and 38% were on no medications, reflecting the large proportion (28%) of patients with less than one seizure per month [7] . In both adults and pediatric series, most patients have a low seizure frequency and are controlled on monotherapy [7, 14] .
Classification of brain tumors in children with approximate frequency
The current classification of primary brain tumors -the classification of the World Health Organization (WHO) -is mainly based on the cell of origin as determined by histologic and molecular features [15] . The 2016 WHO classification represents a break with older schemes that classified tumors based mostly or exclusively on histology [15] . By adding molecular and genetic aspects to the classification, the 2016 WHO scheme adds a level of objectivity that may result in more homogeneous categories with more accurate determination of prognosis and treatment response [15] . Tumors of neuroepithelial tissue derive from glial cellsastrocytes, oligodendrocytes, and ependymal cells -and are termed gliomas. Gliomas account for approximately half of all primary brain tumors and for approximately two thirds of primary malignant brain tumors in children and adolescents [1, 3] . The main tumor of embryonal origin is the medulloblastoma. As the clinical presentation of brain tumors varies by location, a frequently used topographical classification further distinguishes between supratentorial and infratentorial tumors. Approximately 50-60% of primary pediatric brain tumors are supratentorial in location, most of which are of astrocytic origin [1, 3] . Approximately 35-45% of primary pediatric brain tumors are infratentorial, most of which are of neuronal or glial in origin [1, 3] . Prior to providing a detailed description on the characteristics of seizures in each tumor type, we will briefly summarize the most salient characteristics of the most frequent tumors. Detailed descriptions of the clinical presentation, the different tumor types, and the specialized details of the pathology classifications are beyond the scope of this manuscript and can be found elsewhere [15] [16] [17] . Even if the histology is classified as supratentorial or infratentorial to reflect their most common locations, tumors of any histology can appear in either region ( Table 1) .
The 2016 WHO classification of tumors of the central nervous system [15] highlights the need for classification schemes with more homogeneous groups and subgroups. Within broad histologic categories such as "low-grade gliomas" the included tumors vary greatly in terms of molecular and genetic features, response to treatment, and prognosis [15, 17] . This more granular classification of tumors may lead to a more precise and reproducible staging [17] .
Supratentorial tumors
The most common clinical presentation of supratentorial tumors is with unspecified symptoms of increased intracranial pressure (47%), seizures (38%), papilledema (21%), focal neurological signs (17%), headache (11%), hemiplegia (10%), nausea and vomiting (8%), and macrocephaly (6%) [8] . The most common supratentorial tumors are astrocytomas, gangliogliomas, dysembryoplastic neuroepithelial tumors, and oligodendrogliomas. a) Astrocytomas represent approximately one third of all intracranial tumors and the most common histology in the supratentorial region [1, 3] . The World Health Organization classification grades tumors according to an increasing level of malignancy so that grade I is benign, grade II is low grade, grade III is anaplastic or moderately malignant, and grade IV is highly malignant [15] . Fortunately, most pediatric astrocytomas are low grade. The most common pediatric astrocytoma is pilocytic astrocytoma (grade I) which occurs most frequently in the cerebellum, hence we will discuss it under the infratentorial tumors. Grade II diffuse astrocytomas represent approximately 15% of pediatric astrocytomas and have a biphasic distribution with peaks at 2-4 years of age and in adolescence [18] . They appear most commonly in the frontal and temporal lobes as heterogeneous masses [18] . Pathologically, they consist of a fibrillary pattern that infiltrates neighboring brain structures [18] . Their 5-year survival rate varies between 50-100% depending on the extent of surgical resection [18] . Anaplastic astrocytoma (grade III) and glioblastoma multiforme (grade IV) peak at 9-10 years of age and appear most frequently as supratentorial masses with cystic components and necrosis being more frequent with increasing malignancy [18] . Pathologically, they consist of increased cellularity, pleomorphism, and in grade IV, vascular proliferation and areas of necrosis [18] . Their 5-year survival rates are approximately 15-30% [18] . b) Gangliogliomas (Fig. 1 ) represent approximately 3% of brain tumors and 6% of supratentorial pediatric brain tumors [18] . They peak in adolescence and the most common presenting sign is seizures [18] . They appear most frequently in the temporo-parieto-occipital regions followed by the frontal lobes and the posterior fossa [19] [20] [21] . They appear as an enhancing mass with partially cystic appearance in at least 40% of the cases [19] . Calcification can be found in 40-50% of cases [20] . Pathologically, they consist of a mixture of neoplastic glial and neuronal elements: clusters of large ganglion-like neurons mixed with neoplastic astrocytes [19, 21] . Most pediatric gangliogliomas are benign (World Health Organization grade I) [19, 21] . The 5-year survival approaches 100%, but depending on the extent of the resection tumors may recur within 5-years of resection [22] . c) Dysembrioplastic neuroepitelial tumors (DNETs) (Fig. 2) are rare, represent approximately 1% of pediatric brain tumors, and appear most frequently in older children [18, 23] . They appear as a well-circumscribed cystic mass most commonly centered in the cerebral cortex, particularly frequent in the temporal lobe [18, 24] . Pathologically, they consist of columns of axon and oligodendroglial bundles that surround neurons floating in an eosinophilic matrix; DNETs are slow-growing and they are frequently associated with cortical dysplasias [18] . The 5-year survival approaches 100%, although they can recur after surgical resection [24] . d) Oligodendrogliomas are rare representing 1-2% of pediatric brain tumors [3, 25] . They appear as a mass with nodular calcifications in the cerebral hemispheres [18] . Pathologically, they consist of a honeycomb structure with a monotonous collection of uniform rounded cells with clear cytoplasm.
Oligodendrogliomas usually appear as a mixed glioma with different histologic components, so that the 5-year survival is variable depending on the other components of the tumor. e) Supratentorial primitive neuroectodermal tumors represent approximately 5% of all pediatric supratentorial tumors [18] . They peak in the first 5 years of life, sometimes as a congenital tumor [18] . They appear in the cerebral hemispheres as large, heterogeneous masses, often with necrosis, cystic degeneration, calcification, and osseous erosion [18] . Their histology is similar but the prognosis is worse to that of the most frequent infratentorial primitive neuroectodermal tumor: the medulloblastoma [18] .
Infratentorial tumors
The most common clinical presentation of posterior fossa tumors is with nausea and vomiting (75%), headache (67%), abnormal gait and coordination difficulties (60%), and papilledema (34%) [8] . The most common clinical presentation of brain stem tumors is with abnormal gait and coordination difficulties (78%), cranial nerve palsies (52%), pyramidal signs (33%), and headache (23%) [8] . a) Astrocytomas. Pilocytic astrocytomas represent approximately 20% of all pediatric astrocytomas and peak at 5-14 years of age [18, 23] . They appear most commonly in the cerebellum [18, 26] as a well-defined mass or, more commonly, as a single large cyst with a mural node [18] . Pathologically, they consist of an alternation of compact areas with Rosenthal fibers and spongy areas with microcysts; calcification occurs in approximately one fifth of cases [27] . They can remain stable during prolonged periods and their 5-year survival exceeds 90% [18, 26] . This male patient presented with right focal seizures with dyscognitive features at 9 years of age. During his epilepsy work-up a left superior temporal gyrus lesion was found and tentatively classified as malformation of cortical development versus tumor, which remained stable over time. At 16 years of age, he underwent resective epilepsy surgery. The pathology showed glioneuronal tissue with dyslamination, mild increased cellularity, and mild glial atypia consistent with ganglioglioma World Health Organization (classified in 2015 as) grade I. The specimens showed an infiltrating moderately cellular neoplasm composed of glial cells with slightly elongated nuclei, nuclear atypia, karyomegaly, hyperchromasia, and irregularity, admixed with occasional large cells with bizarre large nuclei with prominent nucleoli and abundant cytoplasm, most consistent with dysplastic neurons. Mitoses were difficult to find and there was no necrosis or microvascular proliferation. The glioneural tissue in the background showed mild neuronal crowding, dyslamination, and focal microcolumnar architecture, suggestive of focal cortical dysplasia type I. Immunohistochemistry showed that the GFAP immunostain highlighted moderate to marked subpial, cortical, and white matter reactive astrogliosis; the NeuN immunostain demonstrated the lack of lamination in some areas, and rare microcolumnar architecture; the SMI31 immunostain showed no definitive dysmorphic neurons; the Olig2 immunostain highlighted glial mild nuclear atypia; the Ki67 immunostain showed a low proliferation index; the BRAF V600e, IDH1 (R132H), and p53 immunostains were negative. The patient is seizure free after 3 months of follow-up.
b) Medulloblastomas represent 10-15% of all pediatric brain tumors [1, 3, 23] and peak at 5-9 years of age [18] . In contrast with most other pediatric brain tumors where there is no gender differences, there is more than twofold preference for males [18] . They appear as a large gadolinium-enhanced mass in the fourth ventricle, frequently obstructing the cerebrospinal fluid flow and causing hydrocephalus [18] . Pathologically, they consist of densely packed cells with round to oval or carrotshaped hyperchromatic nuclei surrounded by scant cytoplasm [28] . Five-year survival rates in medulloblastoma have drastically improved in the last years and now are 50-70% depending on pathology and age [28] . c) Ependymomas represent 2-14% of pediatric brain tumors [1, 3, 23] with a peak at 0-5 years of age [18] . Approximately two thirds of ependymomas are infratentorial while one third is supratentorial: infratentorial location is more common in patients younger than 3 years of age and supratentorial location is more common in patients older than 3 years of age [29] . They appear as heterogeneous masses with frequent hemorrhage and necrosis [18] . Pathologically, they show ependymal rosettes with tumor cells lining a small central lumen [18] . 5-year survival is 20-80% and highly dependent on extent of surgical resection, age, and location [18] . d) Hypothalamic hamartomas are rare affecting approximately 1/200,000 children and adolescents [30] . They are congenital, non-progressive masses that arise from the ventral hypothalamus and tuber cinereum [30] . They appear as non-enhancing suprasellar masses of gray matter intensity [18] . Pathologically, they consist of abnormally distributed, but cytologically normal small neurons and glia [30] . Five-year survival approaches 100% [18] .
Clinical presentation of the pediatric brain tumors most associated with seizures
Seizures are more commonly seen in specific pediatric brain tumor types, often termed LEATs. Although LEATs are usually of low grade and have low mortality rates [11] , in these patients chronic seizures -which have been estimated to increase mortality by a factor of approximately 5 -may increase their overall mortality [31] [32] [33] . In a series of 34 pediatric patients with refractory epilepsy and primary brain tumors, the most frequent tumor types were ganglioglioma (44%), low-grade astrocytoma (20.6%), dysembryoplastic neuroepithelial tumor (17.7%), and oligodendroglioma (11.8%) [34] . Electroencephalographic (EEG) interictal findings in pediatric brain tumors are unspecific and can point to the location of the tumor, to other locations, or present normal EEG-even in patients with seizures [35] . In this section we summarize the characteristics of seizures most frequently associated with pediatric brain tumors.
Astrocytomas
Seizures are the presenting symptom in at least a third of pediatric patients with astrocytomas [36] . Classic studies showed an inverse relationship between tumor grade and duration of symptoms: the longer the time to diagnosis, the lower the grade [37] . This may partially explain the classical association between longer duration of symptoms before diagnosis and better prognosis [37] . In general, low-grade and well-differentiated astrocytomas have the highest incidence of seizures while high-grade astrocytomas are less likely to present seizures [38, 39] : seizures occur in approximately 75% of low-grade astrocytomas and in approximately 30% of high-grade astrocytomas [12] . Seizure incidence and frequency also depends on tumor location: tumors in the cortex are This male patient presented with right focal seizures with dyscognitive features at 13 years of age. During his epilepsy work-up a left temporal lobe lesion was found and tentatively classified as DNET, which remained stable. At 15 years of age, he underwent resective epilepsy surgery. The pathology showed DNET World Health Organization (classified in 2015) grade I. The pathology report showed that the tumor was not infiltrating adjacent brain parenchyma, had mild cellularity, mild atypia, no mitoses detected, equivocal vascular proliferation, and equivocal necrosis. Immunohistochemistry was negative for BRAF V600e. The patient is seizure free after 18 months of follow-up. more likely to be related to seizures than tumors in the white matter [40] ; similarly tumors in the temporal lobes and perirolandic regions are more likely to cause seizures than tumors in the occipital regions [38] . In general, astrocytomas are associated with seizures in 60-70% of cases at some point of their evolution [38] . The clinical presentation of seizures, related neurological deficits, and electroencephalographic findings are highly dependent on the location and grade of the tumor. Similarly, the degree of seizure control depends on the ability to resect the tumor and the epileptogenic zone. (Fig. 1) Seizures are the most common presenting symptom of gangliogliomas and occur at presentation in 60-70% of cases [20, 22] . The most common seizure type is focal with dyscognitive features followed by focal motor and focal with secondary generalization [19, 21] . Seizure frequency is variable from daily to monthly seizures [21] . The interictal EEG findings in gangliogliomas can be normal or show unilateral, bilaterally independent, bilaterally synchronous, or multifocal discharges [19] . Seizure control in pediatric gangliogliomas is generally good, but can be challenging due to tumor recurrence. In a series of 55 patients with ganglioglioma, after a mean follow-up of 3.3 years, 48 (87%) patients were in Engel class I (1 patient required a reoperation) of whom 37 were not taking any antiepileptic drug [19] . In a series of 30 pediatric patients with ganglioglioma, after a mean follow-up of 3.4 years, 27 (90%) patients were in Engel class I of whom 22 were not taking any antiepileptic drug [21] .
Ganglioglioma

Dysembryoplastic neuroepithelial tumor (DNET) (Fig. 2)
DNETs are rare and they often present with focal seizures with dyscognitive features at a peak age of 7-10 years [41] [42] [43] . Among primary brain tumors, DNET is the most epileptogenic type with seizures in practically 100% of cases [12] . Headache, papilledema, and other signs or symptoms of increased intracranial pressure are rare at presentation or later in the course of the disease [41] [42] [43] . Epilepsy with DNET is typically disabling with frequent (daily to almost daily) seizures and highly refractory to antiepileptic drugs [41, 43] . The most common electro-clinical seizure type is focal with dyscognitive features, although secondarily generalized and primary generalized tonic-clonic seizures are also common [41] [42] [43] . Most patients with DNETs are highly resistant to antiepileptic drugs but surgical resection leads to seizure freedom in more than 85% of cases [44] . DNETs are stable or slow-growing tumors in the borderline between tumor and cortical dysplasia; cortical dysplasia is actually found surrounding DNETs in at least one third of cases [43] . The limit between DNET and cortical dysplasia can be difficult to delineate and patients who undergo lesionectomy have worse seizure outcome than patients who undergo a more extensive resection [45] . The question of whether intraoperative electrocorticography-guided resection improves outcome remains unanswered [46] [47] [48] .
Oligodendroglioma
Seizures are the most common (40-70%) presenting symptom of oligodendrogliomas [49] [50] [51] . Seizures can be focal -most frequent type at onset -or secondarily generalized [50] . Even if pediatric oligodendrogliomas are relatively benign, a changing seizure pattern or clinical worsening can be a sign of tumor progression [50] . Limited data suggest that treatment of pediatric oligodendroglioma leads to seizure control in most patients [52] . In a series that included seven children with oligodendroglioma presenting with seizures all seven became seizure free after treatment and four discontinued antiepileptic medication [52] . However, the literature on seizure outcome of pediatric oligodendroglioma is very limited and, as in other tumors, the degree of seizure control depends on the extent to which the epileptogenic zone is resected.
Hypothalamic harmartoma
The syndrome of epilepsy with hypothalamic hamartoma is rare: a nationwide Swedish study estimated a prevalence of 0.5/100,000 [53] . The hallmark of epilepsy with hypothalamic hamartoma is gelastic seizures: bouts of vocalization with facial contraction [54] . Most frequently, vocalization resembles laughter and facial contraction resembles a smile, although the mechanical nature of the vocalization and facial contraction makes it sometimes appear the vocalization as crying and the facial contraction as grimace in episodes termed dacrystic seizures [54] . Laughter is most often described to occur without mirth. Gelastic and dacrystic semiologies frequently appear as different seizures in the same patient or even as mixed components during the same seizure [54, 55] . An abrupt sympathetic system activation often accompanies gelastic seizures [56] . Gelastic seizures present within the first year of life in most cases [53, 57] , but initially they are not necessarily recognized as abnormal, as illustrated by a patient who won a happy baby contest for having frequent laughter from the first day of life [57] . Over time other seizure types may appear: focal seizures with dyscognitive features, tonic seizures, atonic seizures, and generalized tonic-clonic seizures [53, 54, 57] . The reason why new seizure types develop is unknown because hypothalamic hamartomas are developmental, non-growing masses (technically, not tumors) which should not affect other brain regions over time [58] . It is speculated that frequent interictal epileptiform discharges and seizures from the hypothalamic hamartoma kindle other foci in the cerebral cortex; these secondary foci initially depend on the hypothalamic hamartoma to produce seizures, but might become completely independent if kindled for long-enough periods of time [54] . Patients with epilepsy with hypothalamic hamartoma often have a progressive cognitive and behavioral impairment [54, 58] . Precocious puberty and other endocrine abnormalities are frequent [54, 58] . EEGs are most frequently normal, although asymmetric background, focal slowing, and generalized or focal epileptiform discharges -often lateralized to the predominant side of the hypothalamic hamartoma -are common [53, 54, 57, 58] . When seizures are captured on EEG, the correlate is variable and includes focal or diffuse attenuation, fast activity, slow activity, or spike-wave complexes [54, 57, 58] . The variable EEG patterns of gelastic seizures suggest that the surface EEG captures only seizure spread and not seizure onset [54, 57, 58] . Most patients with epilepsy with hypothalamic hamartoma are highly resistant to antiepileptic drugs [53, 57, 58] . The complete surgical removal or laser ablation of the hypothalamic hamartoma is effective in treating gelastic seizures as well as stop other seizure types (unless the secondary foci have become completely independent), and often halt or reverse the cognitive and behavioral impairment associated with this syndromic presentation [54, 58] .
Seizures in infratententorial tumors
Seizures occur in approximately 6% of pediatric patients with infratentorial tumors [40] . However, seizures are not the most common presenting symptom of infratentorial tumor and typically appear when the tumor has spread or metastasized to the cerebral cortex or when it has caused increased intracranial pressure as illustrated by the fact that more than 95% of children with an infratentorial tumor and seizures have at least other tumor-related symptom [40] . In particular, more common presenting symptoms for infratentorial tumors are headache, nausea and vomiting, abnormal gait, and abnormal ocular movements [8] . Among infratentorial tumors, the most frequent ones presenting with seizures are astrocytoma (5-10% of the cases), ependymoma (10% of the cases), and medulloblastoma (5%) [40] .
Seizures secondary to brain metastases, leukemias, and treatment with chemotherapy and radiotherapy
In contrast to adults where solid metastases represent the most frequent brain tumor, metastatic solid brain tumors are rare in pediatric patients [59, 60] . Among a series of 1135 pediatric brain tumors, only 26 (2.3%) were solid metastases, and most metastases were solitary (65%) and supratentorial (89%) [60] . In a series of 3950 pediatric patients with a solid primary cancer outside the brain, 54 (1.4%) had a solid brain metastasis or leptomeningeal disease [59] . A simultaneous diagnosis of primary tumor and brain metastasis was rare (8/26 or 1/54 cases) and the median time between diagnosis of the primary tumor and diagnosis of the brain metastasis was 18-48 months [59, 60] . The most frequent primary solid tumors were sarcomas (especially from bone and kidney) and melanomas [59, 60] . The most common symptom of a brain metastasis is headache, which occurs in 30-40% of cases, but seizures are still one of the most common presenting symptoms occurring in 20-25% of the cases [59, 60] .
More relevant for the pediatric population is the brain involvement in leukemias, as they represent the most frequent (approximately 30% of the total) pediatric cancer type [1] . In children with acute lymphoblastic leukemia, seizures occur in approximately 10-15% of cases [61, 62] . Seizure semiology can be either focal, generalized, or focal with secondary generalization [61] . Mechanisms by which leukemia leads to seizures include leukemic infiltration, thrombosis, and hemorrhage, among others [62] . Perhaps even more relevant is the neurotoxicity of prophylactic brain treatment in leukemia [63, 64] . In pediatric leukemias, especially in acute lymphoblastic leukemia, the brain is a reservoir for potential relapse. Therefore, prophylactic treatment reduces the risk for brain relapse but also increases the probability of severe neurologic side effects and the risk for developing seizures and epilepsy [10] . In fact, in a series of pediatric patients with acute lymphoblastic leukemia, all seizures occurred during acute treatment [61] .
As survival for pediatric cancers increases, the long-term sideeffects of cancer treatment on the brain are of increasing relevance. There are no definitive rules to assign a seizure to a specific treatment, but most chemotherapy-induced seizures occur within hours or days of treatment administration [65] . Drugs associated with seizures include cyclosporin A, cisplatin, and busulphan, but seizures represent one of the dose-limiting toxicity of cancer drugs and many cancer drugs can cause seizures at a high-enough dose typically tested in phases I and II clinical trials [65] . In contrast to seizures induced by chemotherapy, seizures secondary to radiotherapy tend to be persistent and sometimes refractory to treatment [66] . Seizures are a welldescribed complication of radiotherapy involving the brain [67] and can even occur at relatively low radiation doses for non-brain related pathology [66] . In the long term, chemotherapy and radiotherapy can also cause secondary tumors in the brain with the potential for further seizures [68, 69] .
Pathophysiological mechanisms by which brain tumors cause seizures
The relationship between brain tumors and seizures can be explained as tumor epileptogenicity: the tumor may contain an abnormal distribution of cells or may excrete molecules that can make the tumor tissue itself epileptogenic; or as peritumoral epileptogenicity: the tumor may modify the peritumoral microenvironment into an epileptogenic zone [70] . The mechanisms through which brain tumors cause seizures are probably multifactorial and include a combination of: (1) metabolic changes in peritumoral brain, (2) morphologic changes in peritumoral brain, (3) secondary epileptogenesis, (4) neurotransmitter changes in peritumoral brain, (5) immunologic changes in peritumoral brain, and (6) presence of blood products, gliosis, and necrosis [18, 38] . Peritumoral brain tissue may be more alkaline because of peritumoral astrocytosis or infiltration by glial tumor cells [38] . Alkalosis leads to increased conductance to Ca 2+ through the Nmethyl-D-aspartate (NMDA) receptor [71] and decreased conductance to Cl À through the gamma-aminobutyric acid (GABA)
receptor [72] . On the other hand, insufficient vascular supply to meet the needs of elevated tumor metabolism or just mechanical compression of brain tissue leads to hypoxia and acidosis [70] . The acidic and hypoxic metabolic environment in the peritumoral tissue may disrupt neuronal and glial function, although the exact mechanisms leading to epileptogenesis are unclear [70] . The brain tissue around brain tumors -especially in gangliogliomas and DNETs -is characterized by cortical disorganization and, sometimes, frank focal cortical dysplasia [73] [74] [75] . The presence of continuous spiking related to a brain tumor is likely to be a marker of dysplasia [73] . Abnormal neuronal morphology, aberrant neuronal migration, and abnormal pattern of synapses may explain epileptogenicity in the peritumoral tissue [12] . In addition, astrocytes play an important role in the regulation of neuronal function [76] . If their buffering and support function is disrupted by brain tissue or peritumoral edema, the resultant dysfunction in neuronal excitability may lead to seizures [76] . Kindling refers to the process by which an active focus of interictal epileptiform activity or seizures promotes abnormal neuronal networks that eventually are able to independently generate interictal epileptiform activity or seizures [77] . This secondary focus can occur close to the primary focus or at a distant place [77] . Brain tumors can be an active focus of interictal epileptiform activity and seizures and, therefore, are able to generate secondary epileptogenic foci around the tumor or distant to it [78] .
An imbalance between excitatory and inhibitory synaptic transmission may further contribute to epileptogenesis in tumors [79] . Local concentrations of glutamate and GABA are variable in the peritumoral tissue [12] . Further, the subunit composition of neurotransmitter receptors also changes around the tumor, potentially promoting excitability [79] . The immune response to the brain tumor fights its growth and spread but can also increase local excitability [38, 70] . Physical destruction of parts of neuronal networks and an imbalance of inhibitory and excitatory cytokines may promote epileptogenicity [38, 70] . Blood products, necrotic tissue, and gliosis in or around the tumor may promote the occurrence of interictal epileptiform activity and seizures by direct irritation or alteration of the microenvironment [12, 38, 70] . Finally, different tumor histologies, different locations within the brain, and different genetic factors in the tumor and the patient may help explain differences in seizure frequency among different patients [12, 38, 70] .
Treatment of seizures caused by pediatric brain tumors
Both surgical and medical treatment of brain tumor addresses the primary cause of seizures and reduces seizure frequency in most cases. The extent of surgical resection in brain tumors and epilepsy is a debated topic [46] . If the epileptogenic zone is peritumoral, then removing the tumor alone might not necessarily lead to seizure freedom [70] . It can also be argued that once the brain tumor is removed, the peritumoral tissue will tend to normalize [70] . In fact, pediatric brain tumor and epilepsy series show Engel class I outcome in more than 80% solely with total tumor resection, without further epilepsy surgery [80, 81] . Additionally, in a series of 23 pediatric patients with intractable epilepsy associated with brain tumors, complete tumor resection led to better seizure outcome than incomplete tumor resection but there was no difference in seizure outcome between the 13 patients who underwent only lesionectomy and the 10 patients who underwent epilepsy surgery [81] . Certain tumors like gangliogliomas and DNETs are frequently associated with cortical dysplasia [73] [74] [75] and may benefit more from a more extensive resection, possibly under electrocorticography guidance. In summary, the extent of surgical resection in brain tumors with epilepsy is not well established [46] , the correlation between resection of the irritative zone detected by intraoperative electrocorticography and outcome is variable [82] , and tumor resection should be individualized case by case. Other strategies primarily targeted to tumor treatment may help control seizures: a meta-analysis of the treatment of low-grade glioma showed that both chemotherapy and radiotherapy improved seizure outcome even when the tumor size was not reduced [83] . On the other hand, seizure decompensation during tumor treatment can occur with both medical [84] and surgical treatment [85] .
Apart from treating seizures targeting their etiology -the brain tumor -, symptomatic treatment of epilepsy involves the use of antiepileptic drugs. Despite the fact that seizures are frequent in patients with brain tumors, prolonged prophylactic use of antiepileptic drugs is not recommended regardless of tumor type because it does not provide substantial benefit -does not effectively prevent first seizures -but side effects from antiepileptic drugs in the context of chemotherapy are particularly common and occasionally lifethreatening [86] [87] [88] : the risk-benefit ratio recommends watchful waiting. There is insufficient evidence for or against a short perioperative prophylactic treatment around the time of tumor resection [89] [90] [91] [92] , although supportive results in some studies may justify its use on certain occasions [89, 91] . In general, once a first seizure occurs, initiation of antiepileptic drugs is justified [12] because the recurrence risk of seizures in patients with brain tumors is probably similar or higher than the risk of seizure recurrence after 2 unprovoked seizures [93] .
Brain tumors represent an heterogeneous group of etiologies causing seizures and, accordingly, the efficacy of antiepileptic drugs is variable depending not only on the drug efficacy but also on the underlying epilepsy severity [12, 38, 70] . As there is a high degree of uncertainty on how effective antiepileptic drugs are for brain tumors, choices are often made based on the interaction and side effect profile [12, 38, 70] . Classical antiepileptic drugs such as phenobarbital, phenytoin, or carbamazepine should be avoided as they may alter the metabolism of chemotherapeutic agents [18] . Newer drugs such as valproate, lamotrigine, topiramate, zonisamide, and levetiracetam may be the preferred drug treatment in patients with tumors because of their limited interaction with chemotherapy [12, 18] . In addition, valproate has some inherent antitumor effects through inhibition of histone deacetylase [94] . Apart from the modifications that antiepileptic drugs cause on chemotherapeutic agents levels, several chemotherapeutic agents can modify the levels of antiepileptic drugs (Table 2) [95] . A practical approach to the treatment of seizures in brain tumor is suggested in Fig. 3 
Conclusions
Seizures are a common presentation of pediatric brain tumors, especially in supratentorial tumors with involvement of the gray matter, and in certain histologies such as DNET, ganglioglioma, and oligodendroglioma. As there is a high degree of uncertainty on how effective antiepileptic drugs are for seizures caused by brain tumors, choices are often driven by interactions and side effect profile. Classic antiepileptic drugs -phenobarbital, phenytoin, or carbamazepine -should be avoided as they may alter the metabolism of chemotherapeutic agents. Newer drugs -valproate, lamotrigine, topiramate, zonisamide, and levetiracetam -may be the preferred option in patients with tumors because of their limited interaction with chemotherapy.
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